TOPOTECAN+BORTEZOMIB	
GEFITINIB+BORTEZOMIB	The metabolism of Gefitinib can be decreased when combined with Bortezomib.
VINCRISTINE+BORTEZOMIB	The metabolism of Vincristine can be decreased when combined with Bortezomib.
MITOMYCIN+BORTEZOMIB	
VINORELBINE+BORTEZOMIB	The metabolism of Vinorelbine can be decreased when combined with Bortezomib.
PORFIMER+BORTEZOMIB	
GEMCITABINE+BORTEZOMIB	
CARBOPLATIN+BORTEZOMIB	
ETOPOSIDE+BORTEZOMIB	The metabolism of Etoposide can be decreased when combined with Bortezomib.
IRINOTECAN+BORTEZOMIB	The metabolism of Irinotecan can be decreased when combined with Bortezomib.
OSIMERTINIB+BORTEZOMIB	The serum concentration of Bortezomib can be increased when it is combined with Osimertinib.
DOCETAXEL+BORTEZOMIB	The risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib.
BRIGATINIB+BORTEZOMIB	The metabolism of Brigatinib can be decreased when combined with Bortezomib.
BEVACIZUMAB+BORTEZOMIB	Bevacizumab may increase the cardiotoxic activities of Bortezomib.
DOXORUBICIN+BORTEZOMIB	The metabolism of Doxorubicin can be decreased when combined with Bortezomib.
DOXORUBICIN+BORTEZOMIB	The serum concentration of Doxorubicin can be increased when it is combined with Bortezomib.
METHOTREXATE+BORTEZOMIB	
PEMETREXED+BORTEZOMIB	
ICOTINIB+BORTEZOMIB	The metabolism of Icotinib can be decreased when combined with Bortezomib.
CISPLATIN+BORTEZOMIB	
OLMUTINIB+BORTEZOMIB	
ALECTINIB+BORTEZOMIB	
AFATINIB+BORTEZOMIB	
CRIZOTINIB+BORTEZOMIB	The metabolism of Crizotinib can be decreased when combined with Bortezomib.
RAMUCIRUMAB+BORTEZOMIB	
NINTEDANIB+BORTEZOMIB	
ERLOTINIB+BORTEZOMIB	The metabolism of Erlotinib can be decreased when combined with Bortezomib.
NINTEDANIB+COPANLISIB	
NINTEDANIB+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Nintedanib.
NINTEDANIB+CYTARABINE	
NINTEDANIB+DENILEUKIN DIFTITOX	
NINTEDANIB+IFOSFAMIDE	
NINTEDANIB+LENALIDOMIDE	
NINTEDANIB+MITOXANTRONE	The serum concentration of Nintedanib can be increased when it is combined with Mitoxantrone.
NINTEDANIB+TEMSIROLIMUS	The serum concentration of Nintedanib can be increased when it is combined with Temsirolimus.
GEFITINIB+LENVATINIB	
VINCRISTINE+LENVATINIB	
MITOMYCIN+LENVATINIB	
VINORELBINE+LENVATINIB	
PORFIMER+LENVATINIB	
IRINOTECAN+LENVATINIB	
OSIMERTINIB+LENVATINIB	The serum concentration of Lenvatinib can be increased when it is combined with Osimertinib.
BRIGATINIB+LENVATINIB	
DOXORUBICIN+LENVATINIB	
METHOTREXATE+LENVATINIB	
PEMETREXED+LENVATINIB	
ICOTINIB+LENVATINIB	
OLMUTINIB+LENVATINIB	
ALECTINIB+LENVATINIB	
AFATINIB+LENVATINIB	
RAMUCIRUMAB+LENVATINIB	
NINTEDANIB+LENVATINIB	
ERLOTINIB+LENVATINIB	
GEFITINIB+LENVATINIB	
VINCRISTINE+LENVATINIB	
MITOMYCIN+LENVATINIB	
VINORELBINE+LENVATINIB	
PORFIMER+LENVATINIB	
IRINOTECAN+LENVATINIB	
OSIMERTINIB+LENVATINIB	The serum concentration of Lenvatinib can be increased when it is combined with Osimertinib.
BRIGATINIB+LENVATINIB	
DOXORUBICIN+LENVATINIB	
METHOTREXATE+LENVATINIB	
PEMETREXED+LENVATINIB	
ICOTINIB+LENVATINIB	
OLMUTINIB+LENVATINIB	
ALECTINIB+LENVATINIB	
AFATINIB+LENVATINIB	
RAMUCIRUMAB+LENVATINIB	
NINTEDANIB+LENVATINIB	
ERLOTINIB+LENVATINIB	
GEFITINIB+COPANLISIB	
DOXORUBICIN+COPANLISIB	
METHOTREXATE+COPANLISIB	
GEFITINIB+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Gefitinib.
IRINOTECAN+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Irinotecan.
DOCETAXEL+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Docetaxel.
DOXORUBICIN+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Doxorubicin.
DOXORUBICIN+CYCLOPHOSPHAMIDE	The serum concentration of Doxorubicin can be increased when it is combined with Cyclophosphamide.
METHOTREXATE+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Methotrexate.
CISPLATIN+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Cisplatin.
GEFITINIB+CYTARABINE	
IRINOTECAN+CYTARABINE	
DOCETAXEL+CYTARABINE	The risk or severity of adverse effects can be increased when Docetaxel is combined with Cytarabine.
DOXORUBICIN+CYTARABINE	
METHOTREXATE+CYTARABINE	
ERLOTINIB+CYTARABINE	
GEFITINIB+DENILEUKIN DIFTITOX	
IRINOTECAN+DENILEUKIN DIFTITOX	
DOXORUBICIN+DENILEUKIN DIFTITOX	
METHOTREXATE+DENILEUKIN DIFTITOX	
IRINOTECAN+IFOSFAMIDE	
DOCETAXEL+IFOSFAMIDE	The risk or severity of adverse effects can be increased when Docetaxel is combined with Ifosfamide.
DOXORUBICIN+IFOSFAMIDE	The metabolism of Ifosfamide can be decreased when combined with Doxorubicin.
METHOTREXATE+IFOSFAMIDE	
GEFITINIB+LENALIDOMIDE	
DOXORUBICIN+LENALIDOMIDE	
METHOTREXATE+LENALIDOMIDE	
DOCETAXEL+MITOXANTRONE	The risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoxantrone.
DOXORUBICIN+MITOXANTRONE	The serum concentration of Doxorubicin can be increased when it is combined with Mitoxantrone.
METHOTREXATE+MITOXANTRONE	
IRINOTECAN+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Irinotecan.
DOXORUBICIN+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Doxorubicin.
DOXORUBICIN+PACLITAXEL	The serum concentration of Doxorubicin can be increased when it is combined with Paclitaxel.
METHOTREXATE+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Methotrexate.
GEFITINIB+TEMSIROLIMUS	
IRINOTECAN+TEMSIROLIMUS	
DOXORUBICIN+TEMSIROLIMUS	The serum concentration of Doxorubicin can be increased when it is combined with Temsirolimus.
METHOTREXATE+TEMSIROLIMUS	
AFATINIB+TEMSIROLIMUS	The serum concentration of Afatinib can be increased when it is combined with Temsirolimus.
TOPOTECAN+LENVATINIB	
GEMCITABINE+LENVATINIB	
ETOPOSIDE+LENVATINIB	
DOCETAXEL+LENVATINIB	The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.
BEVACIZUMAB+LENVATINIB	Bevacizumab may increase the cardiotoxic activities of Lenvatinib.
CISPLATIN+LENVATINIB	
CRIZOTINIB+LENVATINIB	Crizotinib may increase the QTc-prolonging activities of Lenvatinib.
TOPOTECAN+LENVATINIB	
GEMCITABINE+LENVATINIB	
ETOPOSIDE+LENVATINIB	
DOCETAXEL+LENVATINIB	The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.
BEVACIZUMAB+LENVATINIB	Bevacizumab may increase the cardiotoxic activities of Lenvatinib.
CISPLATIN+LENVATINIB	
CRIZOTINIB+LENVATINIB	Crizotinib may increase the QTc-prolonging activities of Lenvatinib.
ERLOTINIB+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Erlotinib.
DOCETAXEL+DENILEUKIN DIFTITOX	The risk or severity of adverse effects can be increased when Docetaxel is combined with Denileukin diftitox.
GEFITINIB+IFOSFAMIDE	
ERLOTINIB+IFOSFAMIDE	
IRINOTECAN+LENALIDOMIDE	
DOCETAXEL+LENALIDOMIDE	The risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.
GEFITINIB+MITOXANTRONE	
IRINOTECAN+MITOXANTRONE	
GEFITINIB+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Gefitinib.
DOCETAXEL+TEMSIROLIMUS	The risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.
CARBOPLATIN+LENVATINIB	
CARBOPLATIN+LENVATINIB	
IRINOTECAN+COPANLISIB	
DOCETAXEL+COPANLISIB	
ERLOTINIB+COPANLISIB	
PEMETREXED+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Pemetrexed.
CISPLATIN+CYTARABINE	
AFATINIB+CYTARABINE	
ERLOTINIB+DENILEUKIN DIFTITOX	
ERLOTINIB+LENALIDOMIDE	
ERLOTINIB+MITOXANTRONE	
DOCETAXEL+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Docetaxel.
ERLOTINIB+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Erlotinib.
VINCRISTINE+TEMSIROLIMUS	The excretion of Vincristine can be decreased when combined with Temsirolimus.
OSIMERTINIB+TEMSIROLIMUS	The serum concentration of Temsirolimus can be increased when it is combined with Osimertinib.
ICOTINIB+TEMSIROLIMUS	
OLMUTINIB+TEMSIROLIMUS	
RAMUCIRUMAB+TEMSIROLIMUS	
ERLOTINIB+TEMSIROLIMUS	
VINCRISTINE+CYTARABINE	
RAMUCIRUMAB+CYTARABINE	
CISPLATIN+PACLITAXEL	Cisplatin may increase the myelosuppressive activities of Paclitaxel.
MITOMYCIN+TEMSIROLIMUS	
AFATINIB+COPANLISIB	
AFATINIB+CYCLOPHOSPHAMIDE	The serum concentration of Afatinib can be increased when it is combined with Cyclophosphamide.
MITOMYCIN+CYTARABINE	
ETOPOSIDE+CYTARABINE	
VINCRISTINE+IFOSFAMIDE	
BEVACIZUMAB+PACLITAXEL	Bevacizumab may increase the cardiotoxic activities of Paclitaxel.
PEMETREXED+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pemetrexed.
PEMETREXED+TEMSIROLIMUS	
OSIMERTINIB+CYTARABINE	The serum concentration of Cytarabine can be increased when it is combined with Osimertinib.
BEVACIZUMAB+CYTARABINE	Bevacizumab may increase the cardiotoxic activities of Cytarabine.
PEMETREXED+CYTARABINE	
ICOTINIB+CYTARABINE	
OLMUTINIB+CYTARABINE	
ALECTINIB+CYTARABINE	
VINCRISTINE+LENALIDOMIDE	
VINCRISTINE+MITOXANTRONE	The serum concentration of Vincristine can be decreased when it is combined with Mitoxantrone.
VINCRISTINE+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vincristine.
VINCRISTINE+PACLITAXEL	The excretion of Vincristine can be decreased when combined with Paclitaxel.
ETOPOSIDE+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Etoposide.
AFATINIB+PACLITAXEL	The serum concentration of Afatinib can be increased when it is combined with Paclitaxel.
PORFIMER+TEMSIROLIMUS	
BRIGATINIB+TEMSIROLIMUS	
CISPLATIN+TEMSIROLIMUS	
ALECTINIB+TEMSIROLIMUS	
VINCRISTINE+COPANLISIB	
VINCRISTINE+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Vincristine.
VINCRISTINE+CYCLOPHOSPHAMIDE	The excretion of Vincristine can be decreased when combined with Cyclophosphamide.
VINORELBINE+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Vinorelbine.
GEMCITABINE+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Gemcitabine.
ETOPOSIDE+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Etoposide.
RAMUCIRUMAB+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Ramucirumab.
VINORELBINE+CYTARABINE	
PORFIMER+CYTARABINE	
BRIGATINIB+CYTARABINE	
CRIZOTINIB+CYTARABINE	The metabolism of Cytarabine can be decreased when combined with Crizotinib.
AFATINIB+DENILEUKIN DIFTITOX	
AFATINIB+IFOSFAMIDE	
PEMETREXED+LENALIDOMIDE	
CISPLATIN+LENALIDOMIDE	
AFATINIB+LENALIDOMIDE	
AFATINIB+MITOXANTRONE	The serum concentration of Afatinib can be decreased when it is combined with Mitoxantrone.
VINORELBINE+TEMSIROLIMUS	
ETOPOSIDE+TEMSIROLIMUS	
TOPOTECAN+CYTARABINE	
VINCRISTINE+DENILEUKIN DIFTITOX	
CISPLATIN+IFOSFAMIDE	
MITOMYCIN+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mitomycin.
GEMCITABINE+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemcitabine.
ALECTINIB+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Alectinib.
RAMUCIRUMAB+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ramucirumab.
OSIMERTINIB+COPANLISIB	The serum concentration of Copanlisib can be increased when it is combined with Osimertinib.
ICOTINIB+COPANLISIB	
OLMUTINIB+COPANLISIB	
TOPOTECAN+CYCLOPHOSPHAMIDE	The serum concentration of Topotecan can be increased when it is combined with Cyclophosphamide.
PORFIMER+CYCLOPHOSPHAMIDE	
OSIMERTINIB+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Osimertinib.
ICOTINIB+CYCLOPHOSPHAMIDE	
OLMUTINIB+CYCLOPHOSPHAMIDE	
ALECTINIB+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Alectinib.
CRIZOTINIB+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Crizotinib.
CISPLATIN+DENILEUKIN DIFTITOX	
RAMUCIRUMAB+LENALIDOMIDE	
PEMETREXED+MITOXANTRONE	
CISPLATIN+MITOXANTRONE	
VINORELBINE+PACLITAXEL	Paclitaxel may increase the neurotoxic activities of Vinorelbine.
PORFIMER+PACLITAXEL	
CARBOPLATIN+PACLITAXEL	Carboplatin may increase the myelosuppressive activities of Paclitaxel.
OSIMERTINIB+PACLITAXEL	The serum concentration of Paclitaxel can be increased when it is combined with Osimertinib.
BRIGATINIB+PACLITAXEL	
ICOTINIB+PACLITAXEL	
OLMUTINIB+PACLITAXEL	
CRIZOTINIB+PACLITAXEL	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Crizotinib.
RAMUCIRUMAB+DENILEUKIN DIFTITOX	
PEMETREXED+IFOSFAMIDE	
RAMUCIRUMAB+MITOXANTRONE	
MITOMYCIN+COPANLISIB	
ETOPOSIDE+COPANLISIB	
PEMETREXED+COPANLISIB	
CISPLATIN+COPANLISIB	
RAMUCIRUMAB+COPANLISIB	
MITOMYCIN+CYCLOPHOSPHAMIDE	Cyclophosphamide may increase the cardiotoxic activities of Mitomycin.
BRIGATINIB+CYCLOPHOSPHAMIDE	
BEVACIZUMAB+CYCLOPHOSPHAMIDE	Bevacizumab may increase the cardiotoxic activities of Cyclophosphamide.
MITOMYCIN+DENILEUKIN DIFTITOX	
PORFIMER+DENILEUKIN DIFTITOX	
ETOPOSIDE+DENILEUKIN DIFTITOX	
OSIMERTINIB+DENILEUKIN DIFTITOX	
BEVACIZUMAB+DENILEUKIN DIFTITOX	Bevacizumab may increase the cardiotoxic activities of Denileukin diftitox.
PEMETREXED+DENILEUKIN DIFTITOX	
ICOTINIB+DENILEUKIN DIFTITOX	
OLMUTINIB+DENILEUKIN DIFTITOX	
ALECTINIB+DENILEUKIN DIFTITOX	
MITOMYCIN+IFOSFAMIDE	
ETOPOSIDE+IFOSFAMIDE	
BEVACIZUMAB+IFOSFAMIDE	Bevacizumab may increase the cardiotoxic activities of Ifosfamide.
ALECTINIB+IFOSFAMIDE	
RAMUCIRUMAB+IFOSFAMIDE	
MITOMYCIN+LENALIDOMIDE	
VINORELBINE+LENALIDOMIDE	
PORFIMER+LENALIDOMIDE	
ETOPOSIDE+LENALIDOMIDE	
OSIMERTINIB+LENALIDOMIDE	
BRIGATINIB+LENALIDOMIDE	
BEVACIZUMAB+LENALIDOMIDE	Bevacizumab may increase the cardiotoxic activities of Lenalidomide.
ICOTINIB+LENALIDOMIDE	
OLMUTINIB+LENALIDOMIDE	
ALECTINIB+LENALIDOMIDE	
CRIZOTINIB+LENALIDOMIDE	
MITOMYCIN+MITOXANTRONE	
VINORELBINE+MITOXANTRONE	
PORFIMER+MITOXANTRONE	
OSIMERTINIB+MITOXANTRONE	
BRIGATINIB+MITOXANTRONE	
BEVACIZUMAB+MITOXANTRONE	Bevacizumab may increase the cardiotoxic activities of Mitoxantrone.
ICOTINIB+MITOXANTRONE	
OLMUTINIB+MITOXANTRONE	
ALECTINIB+MITOXANTRONE	
TOPOTECAN+PACLITAXEL	The serum concentration of Topotecan can be increased when it is combined with Paclitaxel.
VINORELBINE+COPANLISIB	
PORFIMER+COPANLISIB	
BRIGATINIB+COPANLISIB	
BEVACIZUMAB+COPANLISIB	
ALECTINIB+COPANLISIB	
VINORELBINE+DENILEUKIN DIFTITOX	
BRIGATINIB+DENILEUKIN DIFTITOX	
CRIZOTINIB+DENILEUKIN DIFTITOX	
VINORELBINE+IFOSFAMIDE	
PORFIMER+IFOSFAMIDE	
OSIMERTINIB+IFOSFAMIDE	The serum concentration of Ifosfamide can be increased when it is combined with Osimertinib.
ICOTINIB+IFOSFAMIDE	
OLMUTINIB+IFOSFAMIDE	
CRIZOTINIB+IFOSFAMIDE	The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Crizotinib resulting in a loss in efficacy.
TOPOTECAN+LENALIDOMIDE	
GEMCITABINE+LENALIDOMIDE	
GEMCITABINE+MITOXANTRONE	
CRIZOTINIB+MITOXANTRONE	
GEMCITABINE+IFOSFAMIDE	
BRIGATINIB+IFOSFAMIDE	
TOPOTECAN+DENILEUKIN DIFTITOX	
GEMCITABINE+DENILEUKIN DIFTITOX	
TOPOTECAN+IFOSFAMIDE	
TOPOTECAN+MITOXANTRONE	The serum concentration of Topotecan can be increased when it is combined with Mitoxantrone.
ETOPOSIDE+MITOXANTRONE	
